In glioblastoma treatment, the most frequent and most lethal malignant primary brain tumor, fully informed decisions are hindered by a phenomenon known as pseudoprogression. During and after treatment, new MRI findings can either signal progression and poor prognosis, or pseudoprogression and more favorable prognosis. Based on imaging alone, it is often difficult to distinguish true progression from pseudoprogression, possibly delaying treatment decisions and impacting survival and quality of life. Liquid biopsies may offer a solution. In the
PREDICT study, we aim to further develop our blood platelet RNA-based platform into a highly accurate test that is ready for a clinical intervention study. Additionally, similar research is being conducted on pseudoprogression and radionecrosis in brain metastasis and over 2000 RNA samples have already been collected from various other tumor types.
As a postdoctoral researcher, you will be involved the preprocessing and downstream analysis of RNA-seq data, measured in ~300 patients at multiple time points. Your tasks include:
- Data preprocessing, RNA-seq data mapping and quality control, differential expression and machine learning development, integration and validation;
- Implementation of bioinformatic normalization- and correction methods;
- Analysis of previously generated data sets (RNA-seq data of >2000 samples readily available);
- Collaborating with, and supervising the PhD student currently working on the project;
- Publishing your findings in high-impact journals;
- Participating in the application of follow-up grants.